Evaluation of Small Vessel Disease by 3D-rotational Angiography

Launched by CHINESE UNIVERSITY OF HONG KONG · Oct 27, 2020

Keywords

ClinConnect Summary

This clinical trial is studying a condition called cerebral small vessel disease (cSVD), which is related to strokes that occur due to problems with small blood vessels in the brain. The goal is to better understand how these blood vessels change over time and how this knowledge can help improve treatments for patients with strokes caused by small vessel disease. Researchers are looking for participants who are Chinese, between the ages of 30 and 85, and have had a specific type of stroke known as a lacunar infarct.

To be eligible, participants should not have major issues with blood flow in their brain and must not have certain medical conditions that could interfere with the study. If you join the trial, you will undergo imaging tests to help understand your condition better. This research could potentially lead to better treatment options for stroke patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patient is Chinese ONLY
• • 2. Patient is 30 to 85 years of age, inclusive.
• • 3. Patients who have an acute lacunar infarct in diffusion-weighted MRI compatible with small vessel disease in territories supplied by the lateral lenticulostriate arteries without relevant intracranial atherosclerotic stenosis ≥60%.
• • 4. Patient who has no contra-indication for the proposed imaging tests.
• • 5. Patient who understands the purpose and requirements of the study, and has an informed consent.
• • 6. Patient who has Modified Functional Ambulation Classification 4 or above.
• Exclusion Criteria:
• • 1. Stroke etiology uncertain or unrelated to small vessel disease, such as cardioembolism, Moyamoya disease, ICAD or primary angiitis of CNS.
• • 2. Bleeding propensity: active peptic ulcer disease, major systemic hemorrhage within 30 days, thrombocytopenia (platelets \<100 x 109/L), coagulopathy (INR \>1.5).
• • 3. A medical condition that would not allow the patient to adhere to the protocol or complete the study.
• • 4. Patients with severe renal impairment.
• • 5. Patients who are taking warfarin and non-vitamin K antagonist oral anticoagulants would also be excluded.